EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Immediate Postoperative AbnobaVISCUM ® F as an Adjuvant Treatment in Patients Receiving Standard Care after Pancreatic Cancer Resection

Seung Soo Hong iD, Munseok Choi iD, Seoung Yoon Rho iD, Sung Hyun Kim iD, Ho Kyoung Hwang iD, Chang Moo Kang iD

Yonsei Medical Journal · 2025

DOI: 10.3349/ymj.2024.0493 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Yonsei Medical Journal, 2025. Verfasst von Seung Soo Hong und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Yonsei University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Plant Extracts. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: LB ABNOBA Co., Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: AbnobaVISCUM® F is an anti-malignant tumor agent derived from Viscum album, a mistletoe species parasitic to ash trees. It is known to exert anticancer effects by activating the patient's immune system without directly inducing tumor toxicity. We retrospectively investigated the anticancer effect of AbnobaVISCUM® F in patients with resected pancreatic cancer. MATERIALS AND METHODS: We reviewed a total of 985 patients who underwent radical resection for pancreatic cancer between January 2005 and August 2022 at Severance Hospital, Seoul, Korea. Patients were divided into two groups based on whether Abnoba VISCUM® F was administered (Viscum group) or not (Control group), and clinicopathologic characteristics, disease-free survival (DFS) and overall survival (OS) were compared after propensity score matching (PSM). RESULTS: Of the 985 patients, 310 received Viscum therapy at least 12 times (Viscum group), while 590 did not receive it at all (Control group). After PSM, both groups showed similar DFS (p=0.518), whereas the Viscum group showed superior OS (p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsPlant ExtractsHumansMaleFemaleMiddle AgedRetrospective StudiesAgedChemotherapy, AdjuvantViscum albumDisease-Free SurvivalAdult

Stichwörter der Autor:innen

Viscum albumadjuvant treatmentpancreatic cancer

Substanzen

Plant Extracts

Autor:innen und Institutionen

  • Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Yonsei University College of Medicine, Seoul, Korea.
  • Pancreatobiliary Cancer Center, Yonsei Cancer Center, Severance Hospital, Seoul, Korea.
  • Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Yongin Severance Hospital, Yongin, Korea.
  • Pancreatobiliary Cancer Center, Yonsei Cancer Center, Severance Hospital, Seoul, Korea. cmkang@yuhs.ac.

ORCID-Profile: Seung Soo Hong, Munseok Choi, Seoung Yoon Rho, Sung Hyun Kim, Ho Kyoung Hwang, Chang Moo Kang

Förderung

  • LB ABNOBA Co., Ltd.

Zitieren

APA

Hong, S. S., Choi, M., Rho, S. Y., Kim, S. H., Hwang, H. K., & Kang, C. M. (2025). Immediate Postoperative AbnobaVISCUM ® F as an Adjuvant Treatment in Patients Receiving Standard Care after Pancreatic Cancer Resection. Yonsei Medical Journal. https://doi.org/10.3349/ymj.2024.0493

Vancouver

Hong SS, Choi M, Rho SY, Kim SH, Hwang HK, Kang CM. Immediate Postoperative AbnobaVISCUM ® F as an Adjuvant Treatment in Patients Receiving Standard Care after Pancreatic Cancer Resection. Yonsei Medical Journal. 2025. doi:10.3349/ymj.2024.0493

BibTeX
@article{Hong2025,
  author = {Hong, Seung Soo and Choi, Munseok and Rho, Seoung Yoon and Kim, Sung Hyun and Hwang, Ho Kyoung and Kang, Chang Moo},
  title = {Immediate Postoperative AbnobaVISCUM ® F as an Adjuvant Treatment in Patients Receiving Standard Care after Pancreatic Cancer Resection},
  journal = {Yonsei Medical Journal},
  year = {2025},
  doi = {10.3349/ymj.2024.0493}
}
Kostenlos starten →